UroGen shareholders approve 1M share equity plan increase, re-elect all directors

UroGen Pharma Ltd.

Shareholders approved 2017 Equity Incentive Plan amendment adding 1,000,000 ordinary shares to the reserve.
All seven director nominees elected: Arie Belldegrun, Elizabeth Barrett, Cynthia Butitta, Stuart Holden, James Robinson, Leana Wen, Daniel Wildman.
Advisory vote on executive compensation approved (25.1M for, 3.2M against).
PricewaterhouseCoopers LLP ratified as independent auditor for upcoming year (36.8M for).
Articles of Association amended to align shareholder proposal eligibility with Israeli Companies Law.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.